REVELATION BIOSCIENCES INC (REVB) Stock News
NASDAQ:REVB - Nasdaq - US76135L5075 - Common Stock
REVB Latest News and Analysis
Revelation Biosciences Starts its PRIME Phase 1b Clinical Study of Gemini in CKD Patients
Revelation Biosciences Inc. Reminds You to Vote for the Special Meeting on January 17, 2025
Nasdaq Grants Revelation Biosciences Inc. Continued Listing
These stocks are making the most noise in today's session. Stay tuned for the latest updates!
Which stocks are most active on Thursday?
Which stocks are gapping on Thursday?
Let's delve into the US markets on Thursday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.
These stocks are moving in today's pre-market session
Before the US market kicks off on Thursday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.
Why Revelation Biosciences (REVB) Stock Is Down 38%
Revelation Biosciences shares are trading lower by 38% during Tuesday's session. The company agreed to a $4M warrant exercise, closing December 3.
Revelation Biosciences Inc. Announces Exercise of Warrants for $4 Million in Gross Proceeds
Revelation Biosciences Inc. Announces FDA Acceptance of Gemini IND
Revelation Biosciences, Inc. Completes the GMP Manufacture of Gemini Clinical Drug Supply
Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2024
Revelation Biosciences’ Gemini Induces Dose Dependent Significant Increases in IL-10
Revelation Biosciences Inc. Announces Exercise of Warrants for $3.8 Million in Gross Proceeds
REVB Stock Earnings: Revelation Biosciences Misses EPS for Q2 2024
REVB stock results show that Revelation Biosciences missed analyst estimates for earnings per share the second quarter of 2024.
REVB Stock Earnings: Revelation Biosciences Misses EPS for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Revelation Biosciences (NASDAQ:REVB) just reported results for the second quart...
Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2024
Revelation Biosciences Announces Phase 1 Clinical Study of Gemini Met the Primary Safety Endpoint and Showed Statistically Significant Biomarker Activity
Revelation Biosciences Has Completed Dosing of its First in Human Phase 1 Clinical Study of Gemini
REVB Stock Earnings: Revelation Biosciences Misses EPS for Q1 2024
REVB stock results show that Revelation Biosciences missed analyst estimates for earnings per share the first quarter of 2024.
REVB Stock Earnings: Revelation Biosciences Misses EPS for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Revelation Biosciences (NASDAQ:REVB) just reported results for the first quarte...
Revelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2024
REVB Stock Earnings: Revelation Biosciences Beats EPS for Q4 2023
REVB stock results show that Revelation Biosciences beat analyst estimates for earnings per share the fourth quarter of 2023.
REVB Stock Earnings: Revelation Biosciences Beats EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Revelation Biosciences (NASDAQ:REVB) just reported results for the fourth quart...
Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2023
Revelation Biosciences Inc. Gives Oral Presentation at Advances in Critical Care Nephrology (AKI & CRRT 2024)
Revelation Biosciences Inc. to Participate in a Virtual Fireside Chat at the 36th Annual Roth Conference
